Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
Latest Stories
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn’s Trial
NeuroScientific reports on StemSmart Crohn’s trial: 80% clinical response in five patients; safe, paving Phase 2 and a potential entry to a US$13.8B market.
Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
IMEXHS Wins Major Public Tender in Mexico for Aquila+ Platform
IMEXHS wins Mexico tender for Aquila+ AI radiology, adding US$384k ARR and US$50k fee as 20 sites deploy by June 2026; FY25 profitability improves.
Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announces 94% post-thaw platelet recovery with 3% DMSO no-wash protocol, independent validation for frozen platelets.
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX engages Beyond Drug Development to push Stabl-Im Phase 1 safety trial, targeting H2 2026 start and data for regulatory progress.
AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings
AFT Pharmaceuticals targets over $300m revenue in FY27 after record FY26 earnings; Australasia core, expanding international hubs.
Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance
Nyrada reports strong preclinical Xolatryp efficacy in liver cancer and a US patent allowance, highlighting a ~39% boost vs doxorubicin alone.
OncoSil Medical Secures TGA Approval in Australia for Pancreatic Cancer Device
OncoSil Medical wins TGA approval for OncoSil device to treat unresectable LAPC; ARTG-listed, enabling Australian launch as manufacturing scales up.
Mach7 Technologies Lands New US Customer AMRADNET on 5-Year Deal
Mach7 wins US AMRADNET deal worth A$1.7M, 5-year ARR; deployment cut to 45 days, signaling accelerated growth post-transformation.
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement
Island Pharmaceuticals strengthens US biodefence push with new adviser Mark Herzog, MC2 roles, and Galidesivir progress toward FDA Animal Rule trials.